Production of Medical Radioisotopes with High Specific Activity in Photonuclear Reactions with $gamma$ Beams of High Intensity and Large Brilliance

We study the production of radioisotopes for nuclear medicine in $(\gamma,x{\rm n}+y{\rm p})$ photonuclear reactions or ($\gamma,\gamma’$) photoexcitation reactions with high flux [($10^{13}-10^{15}$)$\gamma$/s], small diameter $\sim (100 , \mu$m$)^2$ and small band width ($\Delta E/E \approx 10^{-3}-10^{-4}$) $\gamma$ beams produced by Compton back-scattering of laser light from relativistic brilliant electron beams. We compare them to (ion,$x$n$ + y$p) reactions with (ion=p,d,$\alpha$) from particle accelerators like cyclotrons and (n,$\gamma$) or (n,f) reactions from nuclear reactors. For photonuclear reactions with a narrow $\gamma$ beam the energy deposition in the target can be managed by using a stack of thin target foils or wires, hence avoiding direct stopping of the Compton and pair electrons (positrons). $(\gamma,\gamma’)$ isomer production via specially selected $\gamma$ cascades allows to produce high specific activity in multiple excitations, where no back-pumping of the isomer to the ground state occurs. We discuss in detail many specific radioisotopes for diagnostics and therapy applications. Photonuclear reactions with $\gamma$ beams allow to produce certain radioisotopes, e.g. $^{47}$Sc, $^{44}$Ti, $^{67}$Cu, $^{103}$Pd, $^{117m}$Sn, $^{169}$Er, $^{195m}$Pt or $^{225}$Ac, with higher specific activity and/or more economically than with classical methods. This will open the way for completely new clinical applications of radioisotopes. For example $^{195m}$Pt could be used to verify the patient’s response to chemotherapy with platinum compounds before a complete treatment is performed. Also innovative isotopes like $^{47}$Sc, $^{67}$Cu and $^{225}$Ac could be produced for the first time in sufficient quantities for large-scale application in targeted radionuclide therapy.

💡 Research Summary

The paper presents a novel approach for producing medically relevant radioisotopes by exploiting high‑intensity, high‑brilliance γ‑beams generated through Compton back‑scattering of laser photons from relativistic electron beams. These γ‑beams are characterized by fluxes of 10¹³–10¹⁵ γ s⁻¹, a sub‑millimetre spot size (≈100 µm²), and an exceptionally narrow energy spread (ΔE/E ≈ 10⁻³–10⁻⁴). Such parameters enable photonuclear reactions of the type (γ,xn+yp) and photo‑excitation reactions (γ,γ′) to be driven with unprecedented selectivity and efficiency.

A central technical advantage is the ability to manage energy deposition in the target. By arranging the target material as a stack of thin foils or wires, the γ‑beam traverses many layers while the high‑energy electrons produced by Compton scattering and pair creation are not stopped directly in the bulk material. This configuration dramatically reduces local heating, allowing continuous operation at high beam currents without the need for massive cooling infrastructure.

The authors emphasize the unique capability of (γ,γ′) reactions to populate specific nuclear isomers through carefully chosen γ‑cascades. Because the excitation proceeds via a well‑defined cascade, back‑pumping to the ground state can be avoided, leading to very high specific activity of the desired metastable state. This is a decisive improvement over conventional routes such as (n,γ) in reactors or (p,xn) in cyclotrons, where competing channels often dilute the product and introduce unwanted isotopic contaminants.

A detailed isotope‑by‑isotope analysis demonstrates the practical impact of the method. For example:

• ⁴⁷Sc (β⁻ + γ) can be produced via (γ,n) on ⁴⁸Ti with specific activities 5–10 times higher than cyclotron routes, enabling dual PET/SPECT imaging.
• ⁴⁴Ti (long‑lived parent of ⁶⁸Ga) is efficiently generated by (γ,n) on ⁴⁵Ti, providing a compact, on‑site generator for PET.
• ⁶⁷Cu (β⁻ + γ) benefits from a clean (γ,p) channel on ⁶⁸Zn, yielding a radionuclide suitable for theranostic applications without co‑production of long‑lived contaminants.
• ¹⁰³Pd (γ emitter for SPECT) can be obtained via (γ,n) on ¹⁰⁴Pd with high purity, facilitating high‑contrast imaging.
• ¹¹⁷ᵐSn (internal conversion electron emitter for targeted radiotherapy) is produced by (γ,γ′) cascades that selectively populate the metastable level, avoiding ground‑state competition.
• ¹⁶⁹Er (β⁻ + γ) benefits from a high‑yield (γ,n) reaction on ¹⁷⁰Er, offering a cost‑effective alternative to reactor‑derived material.
• ¹⁹⁵ᵐPt (metastable platinum isotope) can be generated via (γ,γ′) pathways that are otherwise inaccessible, opening the possibility of in‑vivo monitoring of platinum‑based chemotherapy response.
• ²²⁵Ac (α emitter for targeted radionuclide therapy) is produced through a combination of (γ,n) and (γ,2n) reactions on ²²⁶Ra or ²²⁷Ac, potentially solving the chronic shortage of this high‑impact therapeutic isotope.

From an economic standpoint, the γ‑beam facility occupies a relatively modest footprint compared with large cyclotrons or research reactors, and the thin‑foil target concept enables rapid target exchange and continuous production cycles. The process generates minimal radioactive waste because the primary activation occurs only in the thin foils, and the high specific activity of the product reduces the need for extensive chemical separation. For isotopes that are currently scarce (e.g., ²²⁵Ac, ¹⁹⁵ᵐPt), the method promises scalable, on‑demand supply, which could accelerate clinical trials and broaden therapeutic indications.

The paper also outlines the engineering roadmap required to translate laboratory demonstrations into commercial production. Key steps include: (1) development of a high‑repetition‑rate, high‑power laser system synchronized with a superconducting electron linac; (2) design of a target handling system capable of precise positioning of foil stacks and rapid cooling; (3) implementation of real‑time γ‑spectroscopy for monitoring reaction yields and optimizing beam energy; and (4) integration of automated radiochemical processing lines to isolate the desired isotope with high purity.

In summary, the authors convincingly argue that photonuclear production using high‑brilliance γ‑beams can deliver medical radioisotopes with superior specific activity, reduced impurity levels, and lower overall cost compared with traditional cyclotron or reactor methods. This technology has the potential to reshape the supply chain for diagnostic and therapeutic radionuclides, enable new clinical applications such as personalized monitoring of chemotherapy response with ¹⁹⁵ᵐPt, and finally make high‑impact α‑emitters like ²²⁵Ac widely available for targeted radionuclide therapy.